{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:55:04Z","timestamp":1790096104588,"version":"4.0.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104223 and 82204372"],"award-info":[{"award-number":["82104223 and 82204372"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515110008"],"award-info":[{"award-number":["2020A1515110008"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202102021022, 2023A04J0601, 2024A04J10001, and 2025A03J3308"],"award-info":[{"award-number":["202102021022, 2023A04J0601, 2024A04J10001, and 2025A03J3308"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Municipal Science and Technology Project for Medicine and Healthcare","award":["20211A011044"],"award-info":[{"award-number":["20211A011044"]}]},{"name":"Guangzhou Municipal Key Discipline in Medicine","award":["2025-2027"],"award-info":[{"award-number":["2025-2027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14743-3","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:31:37Z","timestamp":1755862297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system"],"prefix":"10.1186","volume":"25","author":[{"given":"Yaqian","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"3","key":"14743_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"14743_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"14743_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.Cd-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046\u201361. https:\/\/doi.org\/10.1158\/2159-8290.Cd-14-0337.","journal-title":"Cancer Discov"},{"issue":"1","key":"14743_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","volume":"21","author":"Y Li","year":"2023","unstructured":"Li Y, Mao T, Wang J, Zheng H, Hu Z, Cao P, et al. Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. Cell Commun Signal. 2023;21(1):71. https:\/\/doi.org\/10.1186\/s12964-023-01082-8.","journal-title":"Cell Commun Signal"},{"issue":"4","key":"14743_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.Naj.0000742492.40886.52","volume":"121","author":"DS Aschenbrenner","year":"2021","unstructured":"Aschenbrenner DS. New adjuvant drug for lung cancer. Am J Nurs. 2021;121(4):23\u20134. https:\/\/doi.org\/10.1097\/01.Naj.0000742492.40886.52.","journal-title":"Am J Nurs"},{"issue":"7","key":"14743_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M\u2013positive lung cancer. N Engl J Med. 2017;376(7):629\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1612674.","journal-title":"N Engl J Med"},{"key":"14743_CR7","doi-asserted-by":"publisher","unstructured":"J\u00e4nne PA, Yang JCH, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR Inhibitor\u2013Resistant Non\u2013Small-Cell Lung Cancer. New England J Med. 2015;372(18):1689-99.https:\/\/doi.org\/10.1056\/NEJMoa1411817","DOI":"10.1056\/NEJMoa1411817"},{"issue":"2","key":"14743_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig SL. Osimertinib: first global approval. Drugs. 2016;76(2):263\u201373. https:\/\/doi.org\/10.1007\/s40265-015-0533-4.","journal-title":"Drugs"},{"issue":"2","key":"14743_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-Induced Cardiotoxicity: a retrospective review of the FDA Adverse Events Reporting System (FAERS). JACC CardioOncology. 2019;1(2):172\u20138. https:\/\/doi.org\/10.1016\/j.jaccao.2019.10.006.","journal-title":"JACC CardioOncology"},{"issue":"7","key":"14743_CR10","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3390\/ijms18071288","volume":"18","author":"J-F Yang","year":"2017","unstructured":"Yang J-F, Chen Y-Z, Kawabata S, Li Y-H, Wang Y. Identification of Light-Independent Anthocyanin Biosynthesis Mutants Induced by Ethyl Methane Sulfonate in Turnip \u201cTsuda\u201d (Brassica rapa). Int J Mol Sci. 2017;18(7):1288.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"14743_CR11","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","volume":"17","author":"G Goss","year":"2016","unstructured":"Goss G, Tsai C-M, Shepherd FA, Bazhenova L, Lee JS, Chang G-C, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(16)30508-3.","journal-title":"Lancet Oncol"},{"issue":"6","key":"14743_CR12","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1111\/cas.13623","volume":"109","author":"H Akamatsu","year":"2018","unstructured":"Akamatsu H, Katakami N, Okamoto I, Kato T, Kim YH, Imamura F, et al. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Cancer Sci. 2018;109(6):1930\u20138. https:\/\/doi.org\/10.1111\/cas.13623.","journal-title":"Cancer Sci"},{"issue":"2","key":"14743_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"issue":"1","key":"14743_CR14","doi-asserted-by":"publisher","first-page":"100260","DOI":"10.1016\/j.jtocrr.2021.100260","volume":"3","author":"F Crowley","year":"2022","unstructured":"Crowley F, Fitzgerald BG, Bhardwaj AS, Siraj I, Smith C. Life-threatening myositis in a patient with EGFR-mutated NSCLC on osimertinib: case report. JTO Clin Res Rep. 2022;3(1):100260. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100260.","journal-title":"JTO Clin Res Rep"},{"key":"14743_CR15","doi-asserted-by":"publisher","first-page":"100254","DOI":"10.1016\/j.ctarc.2020.100254","volume":"25","author":"P Parafianowicz","year":"2020","unstructured":"Parafianowicz P, Krishan R, Beutler BD, Islam RX, Singh T. Myositis - a common but underreported adverse effect of osimertinib: case series and review of the literature. Cancer Treat Res Commun. 2020;25:100254. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100254.","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"14743_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1177\/10781552211042271","volume":"28","author":"H Sugimoto","year":"2022","unstructured":"Sugimoto H, Matsumoto S, Tsuji Y, Sugimoto K. Elevated serum creatine kinase levels due to osimertinib: a case report and review of the literature. J Oncol Pharm Pract. 2022;28(2):489\u201394. https:\/\/doi.org\/10.1177\/10781552211042271.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"14743_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.21037\/tlcr-22-916","volume":"12","author":"Y Li","year":"2023","unstructured":"Li Y, Liu Y, Zhao Z, Zhang Y. Rhabdomyolysis in a patient with advanced lung cancer treated with osimertinib: a case report. Transl Lung Cancer Res. 2023;12(3):629\u201336. https:\/\/doi.org\/10.21037\/tlcr-22-916.","journal-title":"Transl Lung Cancer Res"},{"issue":"8","key":"14743_CR18","doi-asserted-by":"publisher","first-page":"e67597","DOI":"10.7759\/cureus.67597","volume":"16","author":"A Ram","year":"2024","unstructured":"Ram A, Siu CT, Mukherjee A, Gupta R. Osimertinib-induced myositis in a patient with metastatic non-small cell lung cancer with epidermal growth factor receptor mutation. Cureus. 2024;16(8):e67597. https:\/\/doi.org\/10.7759\/cureus.67597.","journal-title":"Cureus"},{"issue":"12","key":"14743_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.arbres.2020.06.021","volume":"56","author":"M Yamasaki","year":"2020","unstructured":"Yamasaki M, Matsumoto N, Nakano S, Kawamoto K, Taniwaki M, Izumi Y, et al. Osimertinib for the treatment of EGFR mutation-positive lung adenocarcinoma complicated with dermatomyositis. Arch Bronconeumol. 2020;56(12):822\u20133. https:\/\/doi.org\/10.1016\/j.arbres.2020.06.021.","journal-title":"Arch Bronconeumol"},{"issue":"8","key":"14743_CR20","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1016\/j.jtho.2018.03.014","volume":"13","author":"S Fujioka","year":"2018","unstructured":"Fujioka S, Kitajima T, Itotani R. Myositis in a patient with advanced lung cancer treated with osimertinib. J Thorac Oncol. 2018;13(8):e137\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2018.03.014.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"14743_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40264-021-01142-3","volume":"45","author":"D Croteau","year":"2022","unstructured":"Croteau D, Pinnow E, Wu E, Mu\u00f1oz M, Bulatao I, Dal Pan G. Sources of evidence triggering and supporting safety-related labeling changes: a 10-year longitudinal assessment of 22 new molecular entities approved in 2008 by the US Food and Drug Administration. Drug Saf. 2022;45(2):169\u201380. https:\/\/doi.org\/10.1007\/s40264-021-01142-3.","journal-title":"Drug Saf"},{"issue":"6","key":"14743_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40264-018-00792-0","volume":"42","author":"M Pham","year":"2019","unstructured":"Pham M, Cheng F, Ramachandran K. A comparison study of algorithms to detect drug-adverse event associations: frequentist, Bayesian, and machine-learning approaches. Drug Saf. 2019;42(6):743\u201350. https:\/\/doi.org\/10.1007\/s40264-018-00792-0.","journal-title":"Drug Saf"},{"issue":"11","key":"14743_CR23","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1001\/jamainternmed.2019.3066","volume":"179","author":"N Tau","year":"2019","unstructured":"Tau N, Shochat T, Gafter-Gvili A, Tibau A, Amir E, Shepshelovich D. Association between data sources and US food and drug administration drug safety communications. JAMA Intern Med. 2019;179(11):1590\u20132. https:\/\/doi.org\/10.1001\/jamainternmed.2019.3066.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"14743_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf. 2024;47(6):575\u201384. https:\/\/doi.org\/10.1007\/s40264-024-01421-9.","journal-title":"Drug Saf"},{"issue":"7","key":"14743_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/pds.3805","volume":"24","author":"CK Wong","year":"2015","unstructured":"Wong CK, Ho SS, Saini B, Hibbs DE, Fois RA. Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants. Pharmacoepidemiol Drug Saf. 2015;24(7):731\u20137. https:\/\/doi.org\/10.1002\/pds.3805.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"14743_CR26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"issue":"7","key":"14743_CR27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"issue":"6","key":"14743_CR28","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"R B\u00f6hm","year":"2016","unstructured":"B\u00f6hm R, von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, et al. OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS ONE. 2016;11(6):e0157753. https:\/\/doi.org\/10.1371\/journal.pone.0157753.","journal-title":"PLoS ONE"},{"key":"14743_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. https:\/\/doi.org\/10.1186\/1471-2105-12-77.","journal-title":"BMC Bioinformatics"},{"issue":"3","key":"14743_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2174\/1574886310666150729112903","volume":"10","author":"P Dias","year":"2015","unstructured":"Dias P, Penedones A, Alves C, Ribeiro CF, Marques FB. The role of disproportionality analysis of pharmacovigilance databases in safety regulatory actions: a systematic review. Curr Drug Saf. 2015;10(3):234\u201350. https:\/\/doi.org\/10.2174\/1574886310666150729112903.","journal-title":"Curr Drug Saf"},{"issue":"4","key":"14743_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321. https:\/\/doi.org\/10.1007\/s002280050466.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"14743_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"14743_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"14743_CR34","doi-asserted-by":"publisher","unstructured":"Fusaroli M, Salvo F, Khouri C, Raschi E. The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline. Frontiers in Pharmacology. 2024; 15:2024.https:\/\/doi.org\/10.3389\/fphar.2024.1488725","DOI":"10.3389\/fphar.2024.1488725"},{"issue":"1","key":"14743_CR35","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun. 2023;14(1):1070. https:\/\/doi.org\/10.1038\/s41467-023-35961-y.","journal-title":"Nat Commun"},{"issue":"1","key":"14743_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"issue":"11","key":"14743_CR37","first-page":"529","volume":"37","author":"I Beierle","year":"1999","unstructured":"Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther. 1999;37(11):529\u201347.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"14743_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00003088-200544010-00002","volume":"44","author":"MM Cotreau","year":"2005","unstructured":"Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44(1):33\u201360. https:\/\/doi.org\/10.2165\/00003088-200544010-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"14743_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4236\/pp.2011.21004","volume":"2","author":"C-P del Carmen","year":"2011","unstructured":"del Carmen C-P, Flores-Murrieta FJ. Gender differences in the pharmacokinetics of oral drugs. Pharmacology & Pharmacy. 2011;2(1):31\u201341. https:\/\/doi.org\/10.4236\/pp.2011.21004.","journal-title":"Pharmacology & Pharmacy"},{"key":"14743_CR40","doi-asserted-by":"publisher","first-page":"104763","DOI":"10.1016\/j.ebiom.2023.104763","volume":"95","author":"S Zhong","year":"2023","unstructured":"Zhong S, Borlak J. Sex disparities in non-small cell lung cancer: mechanistic insights from a cRaf transgenic disease model. EBioMedicine. 2023;95:104763. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104763.","journal-title":"EBioMedicine"},{"issue":"4","key":"14743_CR41","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1159\/000430307","volume":"36","author":"Y Su","year":"2015","unstructured":"Su Y, Zhang H, Xu F, Kong J, Yu H, Qian B. DNA repair gene polymorphisms in relation to non-small cell lung cancer survival. Cell Physiol Biochem. 2015;36(4):1419\u201329. https:\/\/doi.org\/10.1159\/000430307.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"14743_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5334\/aogh.2419","volume":"85","author":"JA Barta","year":"2019","unstructured":"Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85(1):8. https:\/\/doi.org\/10.5334\/aogh.2419.","journal-title":"Ann Glob Health"},{"key":"14743_CR43","doi-asserted-by":"publisher","first-page":"e000796","DOI":"10.1136\/esmoopen-2020-000796","volume":"5","author":"N Mederos","year":"2020","unstructured":"Mederos N, Friedlaender A, Peters S, Addeo A. Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer. ESMO Open. 2020;5:e000796. https:\/\/doi.org\/10.1136\/esmoopen-2020-000796.","journal-title":"ESMO Open"},{"issue":"8","key":"14743_CR44","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1016\/j.jtho.2018.03.014","volume":"13","author":"S Fujioka","year":"2018","unstructured":"Fujioka S, Kitajima T, Itotani R. Myositis in a patient with advanced lung cancer treated with Osimertinib. J Thorac Oncol. 2018;13(8):e137\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2018.03.014.","journal-title":"J Thorac Oncol"},{"issue":"17","key":"14743_CR45","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012\u201322. https:\/\/doi.org\/10.1093\/eurheartj\/ehv043.","journal-title":"Eur Heart J"},{"issue":"9","key":"14743_CR46","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/cpdd.1095","volume":"11","author":"W Ji","year":"2022","unstructured":"Ji W, Jiang Y, Wei Y, He K, Mu H, Wen Q, et al. Effect of food intake on pharmacokinetics of oral almonertinib: a randomized crossover trial in healthy Chinese participants. Clin Pharmacol Drug Dev. 2022;11(9):1046\u201353. https:\/\/doi.org\/10.1002\/cpdd.1095.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"14743_CR47","doi-asserted-by":"publisher","first-page":"e70053","DOI":"10.1111\/cts.70053","volume":"17","author":"H Zhang","year":"2024","unstructured":"Zhang H, To KKW. Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: symptoms, mechanism, and clinical management. Clin Transl Sci. 2024;17(11):e70053. https:\/\/doi.org\/10.1111\/cts.70053.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"14743_CR48","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257\u201365. https:\/\/doi.org\/10.1016\/s1470-2045(15)70054-9.","journal-title":"Lancet Oncol"},{"issue":"4","key":"14743_CR49","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/cji.0000000000000196","volume":"41","author":"T Liewluck","year":"2018","unstructured":"Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother. 2018;41(4):208\u201311. https:\/\/doi.org\/10.1097\/cji.0000000000000196.","journal-title":"J Immunother"},{"issue":"5","key":"14743_CR50","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3390\/biomedicines12050987","volume":"12","author":"S Miernik","year":"2024","unstructured":"Miernik S, Matusiewicz A, Olesi\u0144ska M. Drug-induced myopathies: a comprehensive review and update. Biomedicines. 2024;12(5):987. https:\/\/doi.org\/10.3390\/biomedicines12050987.","journal-title":"Biomedicines"},{"issue":"9","key":"14743_CR51","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.3390\/ijms21093054","volume":"21","author":"AG Solimando","year":"2020","unstructured":"Solimando AG, Crudele L, Leone P, Argentiero A, Guarascio M, Silvestris N, et al. Immune checkpoint inhibitor-related myositis: from biology to bedside. Int J Mol Sci. 2020;21(9):3054. https:\/\/doi.org\/10.3390\/ijms21093054.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"14743_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","volume":"14","author":"FW Miller","year":"2018","unstructured":"Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. 2018;14(5):255\u201368. https:\/\/doi.org\/10.1038\/nrrheum.2018.48.","journal-title":"Nat Rev Rheumatol"},{"key":"14743_CR53","doi-asserted-by":"publisher","unstructured":"Dem\u0131rel N, Dem\u0131r M. Docetaxel associated myositis. Journal of Chemotherapy.1\u20136.https:\/\/doi.org\/10.1080\/1120009X.2025.2505806","DOI":"10.1080\/1120009X.2025.2505806"},{"issue":"10","key":"14743_CR54","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2169\/internalmedicine.8168-21","volume":"61","author":"S Obayashi","year":"2022","unstructured":"Obayashi S, Tomomatsu K, Urata M, Tanaka J, Niimi K, Hayama N, et al. Rhabdomyolysis caused by gefitinib overdose. Intern Med. 2022;61(10):1577\u201380. https:\/\/doi.org\/10.2169\/internalmedicine.8168-21.","journal-title":"Intern Med"},{"issue":"1","key":"14743_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3949\/ccjm.83a.14120","volume":"83","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia S, Oddis CV, Aggarwal R. Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med. 2016;83(1):37\u201342. https:\/\/doi.org\/10.3949\/ccjm.83a.14120.","journal-title":"Cleve Clin J Med"},{"issue":"4","key":"14743_CR56","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/s1734-1140(11)70601-6","volume":"63","author":"M Tomaszewski","year":"2011","unstructured":"Tomaszewski M, St\u0119pie\u0144 KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep. 2011;63(4):859\u201366. https:\/\/doi.org\/10.1016\/s1734-1140(11)70601-6.","journal-title":"Pharmacol Rep"},{"issue":"3","key":"14743_CR57","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12328-013-0381-2","volume":"6","author":"K Tsuji","year":"2013","unstructured":"Tsuji K, Takemura K, Minami K, Teramoto R, Nakashima K, Yamada S, et al. A case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma. Clin J Gastroenterol. 2013;6(3):255\u20137. https:\/\/doi.org\/10.1007\/s12328-013-0381-2.","journal-title":"Clin J Gastroenterol"},{"key":"14743_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.toxlet.2024.05.005","volume":"397","author":"H Yang","year":"2024","unstructured":"Yang H, Qiu S, Yao T, Liu G, Liu J, Guo L, et al. Transcriptomics coupled with proteomics reveals osimertinib-induced myocardial mitochondrial dysfunction. Toxicol Lett. 2024;397:23\u201333. https:\/\/doi.org\/10.1016\/j.toxlet.2024.05.005.","journal-title":"Toxicol Lett"},{"issue":"2","key":"14743_CR59","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4081\/oncol.2021.547","volume":"15","author":"MD Prenggono","year":"2021","unstructured":"Prenggono MD, Yasmina A, Ariyah M, Wanahari TA, Hasrianti N. The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review. Oncol Rev. 2021;15(2):547. https:\/\/doi.org\/10.4081\/oncol.2021.547.","journal-title":"Oncol Rev"},{"issue":"9","key":"14743_CR60","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.21037\/tlcr-21-600","volume":"10","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Su Z, Lin Y, Xiong Y, Li C, Li J, et al. Prognostic and predictive impact of creatine kinase level in non-small cell lung cancer treated with tyrosine kinase inhibitors. Transl Lung Cancer Res. 2021;10(9):3771\u201381. https:\/\/doi.org\/10.21037\/tlcr-21-600.","journal-title":"Transl Lung Cancer Res"},{"issue":"8","key":"14743_CR61","doi-asserted-by":"publisher","first-page":"e71770","DOI":"10.1371\/journal.pone.0071770","volume":"8","author":"MC Leroy","year":"2013","unstructured":"Leroy MC, Perroud J, Darbellay B, Bernheim L, Konig S. Epidermal growth factor receptor down-regulation triggers human myoblast differentiation. PLoS ONE. 2013;8(8):e71770. https:\/\/doi.org\/10.1371\/journal.pone.0071770.","journal-title":"PLoS ONE"},{"issue":"1","key":"14743_CR62","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12883-019-1490-4","volume":"19","author":"V Nersesjan","year":"2019","unstructured":"Nersesjan V, Hansen K, Krag T, Duno M, Jeppesen TD. Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. BMC Neurol. 2019;19(1):247. https:\/\/doi.org\/10.1186\/s12883-019-1490-4.","journal-title":"BMC Neurol"},{"issue":"8","key":"14743_CR63","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1200\/jco.2003.11.143","volume":"21","author":"MWN Deininger","year":"2003","unstructured":"Deininger MWN, O\u2019Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637\u201347. https:\/\/doi.org\/10.1200\/jco.2003.11.143.","journal-title":"J Clin Oncol"},{"issue":"12","key":"14743_CR64","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16(12):2091\u2013108. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.035.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"14743_CR65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/10428194.2021.1971219","volume":"63","author":"A Bankar","year":"2022","unstructured":"Bankar A, Lipton JH. Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study. Leuk Lymphoma. 2022;63(1):179\u201388. https:\/\/doi.org\/10.1080\/10428194.2021.1971219.","journal-title":"Leuk Lymphoma"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14743-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14743-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14743-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:00:08Z","timestamp":1757480408000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14743-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14743"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14743-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"22 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since all data of our study was originated from public databases with non-identifiable datasets, no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1360"}}